Drug therapy for atrial fibrillation

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 9, 2006, Pages 1121-1131

  Vardas, Panos E ^a,b   Kallergis, Eleftherios M ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b UNIVERSITY OF CRETE   (Greece)

Author keywords

Antiarrhythmic drugs; Atrial fibrillation; Rate control; Rhythm control

Indexed keywords

2' (4 METHOXYPHENYLACETAMIDOMETHYL) N [2 (3 PYRIDYL)ETHYL] 2 BIPHENYLCARBOXAMIDE; ACETYLSALICYLIC ACID; AMIODARONE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ASCORBIC ACID; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISOPYRAMIDE; DOFETILIDE; ENCAINIDE; FISH OIL; FLECAINIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUTILIDE; NEW DRUG; NIP 142; PROCAINAMIDE; PROPAFENONE; QUINIDINE; RSD 1235; SOTALOL; STEROID; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL; WARFARIN;

ASTHMA; ATRIOVENTRICULAR BLOCK; BLEEDING; BRADYCARDIA; CLINICAL TRIAL; CORNEA DISEASE; DISEASE EXACERBATION; DRUG CHOICE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SYNTHESIS; EVIDENCE BASED MEDICINE; HEART ATRIUM FIBRILLATION; HEART ELECTROPHYSIOLOGY; HEART FAILURE; HEART PROARRHYTHMIA; HEART REPOLARIZATION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE REMODELING; HEPATITIS; HUMAN; HYPOTENSION; LUNG FIBROSIS; META ANALYSIS; NEUROTOXICITY; PRACTICE GUIDELINE; QT PROLONGATION; RECURRENT DISEASE; REVIEW; SINUS RHYTHM; SYSTEMATIC REVIEW; THYROID DISEASE; TORSADE DES POINTES;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANTI-ARRHYTHMIA AGENTS; ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; CALCIUM CHANNEL BLOCKERS; ELECTROCARDIOGRAPHY; HUMANS; LONG QT SYNDROME; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; POTASSIUM CHANNEL BLOCKERS; PRACTICE GUIDELINES; RANDOMIZED CONTROLLED TRIALS; TACHYCARDIA, VENTRICULAR; WARFARIN;

EID: 33745445501     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.9.1121     Document Type: Review

References (59)

1. BENZAMIN EJ, WOLF PA, D'AGOSTINO RB, SILBERSHATZ H, KANNEL WB, LEVY D: Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation (1998) 98:946-952.
2. CHUGH SS, BLACKSHEAR JL, SHEN WK, HAMMILL SC, GERSH BJ: Epidemiology and natural history of atrial fibrillation: clinical implications. J. Am. Coll. Cardiol. (2001) 37:371-378.
3. OSTRANDERLD JR, BRANDT RL, KJELSBERG MO, EPSTEIN FH: Electrocardiographic findings among the adult population of a total natural community, Tecumseh, Michigan. Circulation (1965) 31:888-898.
4. FEINBERG WM, BLACKSHEAR JL, LAUPACIS A, KRONMAL R, HART RG: Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch. Intern. Med. (1995) 155(5):469-473.
5. KANNEL WB, ABBOTT RD, SAVAGE DD, MCNAMARA PM: Epidemiologic features of chronic atrial fibrillation. N. Engl. J. Med. (1982) 306(17):1018-1022.
6. WOLF PA, ABBOTT RD, KANNEL WB: Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke (1991) 22:983-988.
7. FURBERG CD, PSATY BM, MANOLIO TA, GARDIN JM, SMITH VE, RAUTAHARJU PM: Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am. J. Cardiol. (1994) 74:236-241.
8. PSATY BM, MANOLIO TA, KULLER LH et al.: Incidence of and risk factors for atrial fibrillation in older adults. Circulation (1997) 96:2455-2461.
9. KRAHN AD, MANFREDA J, TATE RB, MATHEWSON FA, CUDDY TE: The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba follow-up study. Am. J. Med. (1995) 98(5):476-484.
10. WOLF PA, ABBOTT RD, KANNEL WB: The natural history of atrial fibrillation. Atrial fibrillation: a major contributor to stroke in the elderly: the Framingham Study. Arch. Intern. Med. (1987) 147:1561-1564.
11. KOWEY PR, YAN GX, DIMINO TL, KOCOVIC DZ: Overview of the management of atrial fibrillation: what is the current state of the art? J. Cardiovasc. Electrophysiol. (2003) 14(12 Suppl.):S275-S280.
12. MOE GK, ABILDSKOV JA: Atrial fibrillation as a self-sustaining arrhythmia independent of focal discharge. Am. Heart J. (1959) 58:59-70.
13. HAISSAGUERRE M, JAIS P, SHAH DC et al.: Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N. Engl. J. Med. (1998) 339:659-666.
14. ALLESSIE MA, KONINGS K, KIRCHHOF CJ, WIJFFELS M: Electrophysiologic mechanisms of perpetuation of atrial fibrillation. Am. J. Cardiol. (1996) 77:10A-23A.
15. STANLEY NATTEL: New ideas about atrial fibrillation 50 years on. Nature (2002) 415:219-226.
16. WIJFFELS MC, KIRCHHOF CJ, DORLAND R, POWER J, ALLESSIE MA: Electrical remodeling due to atrial fibrillation in chronically instrumented conscious goats: roles of neurohumoral changes, ischemia, atrial stretch, and high rate of electrical activation. Circulation (1997) 96:3710-3720.
17. ALLESSIE MA: Atrial fibrillation-induced electrical remodeling in humans: what is the next step? Cardiovasc. Res. (1999) 44:10-12.
18. WANG J, BOURNE GW, WANG Z et al.: Comparative mechanisms of anti-arrhythmic drug action in experimental atrial fibrillation. Circulation (1993) 88:1030-1044.
19. WIJFFELS MC, DORLAND R, MAST F, ALLESSIE MA: Widening of the excitable gap during pharmacological cardioversion of atrial fibrillation in the goat: effects of cibenzoline, hydroquinidine, flecainide, and D-sotalol. Circulation (2000) 102(2):260-267.
20. FUSTER V, RYDEN LE, ASINGER RW et al.: ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A report of the American College of Cardiology/American Heart Association task force on practice guidelines and the European Society of Cardiology Committee for practice guidelines and policy conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Circulation (2001) 104(17):2118-2150.
21. REISINGER J, GATTERER E, HEINZE G et al.: Prospective comparison of flecainide versus sotalol for immediate cardioversion of atrial fibrillation. Am. J. Cardiol. (1998) 81:1450-1454.
22. MCNAMARA RL, TAMARIZ LJ, SEGAL JB, BASS EB: Management of atrial fibrillation: review of the evidence for the role of pharmacologic therapy, electrical cardioversion, and echocardiography. Ann. Intern. Med. (2003) 139:1018-1033.
23. STEINBECK G, REMP T, HOFFMANN E: Effects of class I drugs on atrial fibrillation. J. Cardiovasc. Electrophysiol. (1998) 9(8 Suppl.):S104-S108.
24. BORGEAT A, GOY JJ, MAENDLY R, KAUFMANN U, GRBIC M, SIGWART U: Flecainide versus quinidine for conversion of atrial fibrillation to sinus rhythm. Am. J. Cardiol. (1986) 58(6):496-498.
25. KHAN IA: Oral loading single dose flecainide for farmacological cardioversion of recent-onset atrial fibrillation. Int. J. Cardiol. (2003) 87:121-128.
26. CAPUCCI A, VILLANI GQ, ASCHIERI D, PIEPOLI M: Safety of oral propafenone in the conversion of recent onset atrial fibrillation to sinus rhythm: a prospective parallel placebo-controlled multicentre study. Int. J. Cardiol. (1999) 68:187-196.
27. ECHT DS, LIEBSON PR, MITCHELL LB et al.: Mortality and morbidity in patients receiving encainide, flecainide, or placebo, the cardiac arrhythmia suppression trial. N. Engl. J. Med. (1991) 324(12):781-788.
28. VARDAS PE, KOCHIADAKIS GE, IGOUMENIDIS NE, TSATSAKS AM, SIMANTIRAKIS EN, CHLOUVERAKIS GI: Amiodarone as a first-choice drug for restoring sinus rhythm in patients with atrial fibrillation. A randomized, controlled study. Chest (2000) 117:1538-1545.
29. KOCHIADAKIS GE, IGOUMENIDIS NE, SOLOMOU MC, KALEBOUBAS MD, CHLOUVERAKIS GI, VARDAS PE: Efficacy of amiodarone for the termination of persistent atrial fibrillation. Am. J. Cardiol. (1999) 83:58-61.
30. KOCHIADAKIS GE, IGOUMENIDIS NE, MARKETOU ME et al.: Procainamide - propafenone - amiodarone: a comparative study on the efficacy and safety of thew anti-arrhythmic agents for the conversion of recent onset atrial fibrillation. Circulation 102(18):II-803. Abstract.
31. KOCHIADAKIS GE, IGOUMENIDIS NE, PARTHENAKIS FG, CHLOUVERAKIS GI, VARDAS PE: Amiodarone versus propafenone for conversion of chronic atrial fibrillation: results of a randomized, controlled study. J. Am. Coll. Cardiol. (1999) 33:966-971.
32. GALVE E, RIUS T, BALLESTER R et al.: Intravenous amiodarone in treatment of recent-onset atrial fibrillation: results of a randomized, controlled study. J. Am. Coll. Cardiol. (1996) 27:1079-1082.
33. DONOVAN KD, POWER BM, HOCKINGS BE et al.: Intravenous flecainide versus amiodarone for recent-onset atrial fibrillation. Am. J. Cardiol. (1995) 75:693-697.
34. KOCHIADAKIS GE, IGOUMENIDIS NE, MARKETOU ME, SOLOMOU MC, KANOUPAKIS EM, VARDAS PE: Low-dose amiodarone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am. J. Cardiol. (1998) 81:995-998.
35. KOCHIADAKIS GE, IGOUMENIDIS NE, MARKETOU ME KALEBOUBAS MD, SIMANTIRAKIS EN VARDAS PE: Low dose amiodarone and sotalol in the treatment of recurrent, symptomatic atrial fibrillation: a comparative, placebo controlled study. Heart (2000) 84:251-257.
36. KOCHIADAKIS GE, IGOUMENIDIS NE: HAMILOS MI et al.: Long-term maintenance of normal sinus rhythm in patients with current symptomatic atrial fibrillation, amiodarone versus propafenone, both in low doses. Chest (2004) 125:377-383.
37. ROY D, TALAJIC M, DORIAN P et al.: Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N. Engl. J. Med. (2000) 342(13):913-920.
38. THE AFFIRM FIRST ANTIARRHYTHMIC DRUG SUBSTUDY INVESTIGATORS: Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. J. Am. Coll. Cardiol. (2003) 42(1):20-29.
39. SINGH BN, SINGH SN, REDA DJ et al.: Amiodarone versus sotalol for atrial fibrillation. N. Engl. J. Med. (2005) 352(18):1861-1872.
40. BOOS CJ, ANDERSON RA, LIP GY: Is atrial fibrillation an inflammatory disorder? Eur. Heart J. (2006) 27(2):136-149.
41. HEALEY JS, BARANCHUK A, CRYSTAL E et al.: Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J. Am. Coll. Cardiol. (2005) 45:1832-1839.
42. WYSE DG, WALDO AL, DIMARCO JP et al.: A comparison of rate control and rhythm control in patients with atrial fibrillation. N. Engl. J. Med. (2002) 347(23):1825-1833.
43. DAVID D, SEGNI ED, KLEIN HO, KAPLINSKY E: Inefficacy of digitalis in the control of heart rate in patients with chronic atrial fibrillation: beneficial effect of an added beta adrenergic blocking agent. Am. J. Cardiol. (1979) 44:1378-1382.
44. RAWLES JM, METCALFE MJ, JENNINGS K: Time of occurrence, duration, and ventricular rate of paroxysmal atrial fibrillation: the effect of digoxin. Br. Heart J. (1990) 63:225-227.
45. LUNDSTROM T, RYDEN L: Ventricular rate control and exercise performance in chronic atrial fibrillation: effects of diltiazem and verapamil. J. Am. Coll. Cardiol. (1990) 16(1):86-90.
46. TAMARIZ, LJ, BASS, EB: Pharmacological rate control of atrial fibrillation. Cardiol. Clin. (2004) 22:35-45.
47. SEGAL JB, MCNAMARA RL, MILLER MR et al.: The evidence regarding the drugs used for ventricular rate control. J. Fam. Pract. (2000) 49(1):47-59.
48. FARSHI R, KISTNER D, SARMA JS, LONGMATE JA, SINGH BN: Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens. J. Am. Coll. Cardiol. (1999) 33(2):304-310.
49. OLSHANSKY B, ROSENFELD LE, WARNER AL et al.: The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation. J. Am. Coll. Cardiol. (2004) 43(7):1201-1208.
50. VAN GELDER IC, HAGENS VE, BOSKER HA et al.: A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N. Engl. J. Med. (2002) 347(23):1834-1840.
51. HOHNLOSER SH, KUCK KH, LILIENTHAL J: Rhythm or rate control in atrial fibrillation - pharmacological Intervention in Atrial Fibrillation (PIAF): a randomiscd trial. Lancet (2000) 356(9244):1789-1794.
52. CARLSSON J, MIKETIC S, WINDELER J et al.: Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J. Am. Coll. Cardiol. (2003) 41(10):1690-1696.
53. OPOLSKI G, TORBICKI A, KOSIOR DA et al.: Rate control versus rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study. Chest (2004) 126(2):476-486.
54. EZEKOWITZ MD, JAMES KE, NAZARIAN SM et al.: Silent cerebral infarction in patients with nonrheumatic atrial fibrillation. The Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. Circulation (1995) 92(8):2178-2182.
55. WIJFFELS MC, CRIJNS HJ: Recent advances in drug therapy for atrial fibrillation. J. Cardiovasc. Electrophysiol. (2003) 14(9 Suppl.):S40-S47.
56. BILLMAN GE: RSD-1235. Cardiome. Curr. Opin. Investig. Drugs (2003) 4:352-354.
57. MATSUDA T, TAKEDA K, ITO M et al.: Atria selective prolongation by NIP-142, an antiarrhythmic agent, of refractory period and action potential duration in guinea pig myocardium. J. Pharmacol. Sci. (2005) 98(1):33-40.
58. KNOBLOCH K, BRENDEL J, PEUKERT S, ROSENSTEIN B, BUSCH AE, WIRTH KJ: Electrophysiological and antiarrhythmic effects of the novel I(Kur) channel blockers, S9947 and S20951, on left versus right pig atrium in vivo in comparison with the I(Kr) blockers dofetilide, azimilide, D,L-sotalol and ibutilide. Naunyn Schmiedebergs Arch. Pharmacol. (2002) 366(5):482-487.
59. BLAAUW Y, GÖGELEIN H, TIELEMAN RG, VAN HUNNIK A, SCHOTTEN U, ALLESSIE MA: 'Early' Class III drugs for the treatment of atrial fibrillation efficacy and atrial selectivity of AVE0118 in remodeled atria of the goat. Circulation (2004) 110:1717-1724.